Inmed To Participate In The H.C. Wainwright 27Th Annual Global Investment Conference

(MENAFN- Newsfile Corp) Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online.

In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025 , the world's leading forum for Alzheimer's disease and dementia research.

H.C. Wainwright 27th Annual Global Investment Conference
Presentation Link:

The webcast will be available for 90 days at the link above or on the InMed Investor Relations Events page:

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit .

MENAFN05092025004218003983ID1110023677